medcelerator · clinician one-pager

Once-Daily Pill for Adults with Parkinson’s Disease

Juvmo (tavapadon) — selective D1/D5 dopamine agonist for Parkinson’s disease in adults

FDA Approved · United States · October 8, 2026

Condition: Parkinson’s Disease

Who this is for

This is for adults with Parkinson’s disease — and caregivers — who need a labelled once-daily oral option that can be used with or without levodopa. It explains FDA approval of Juvmo (tavapadon) on 25 September 2026, the TEMPO-1/2/3 studies (NCT04201093, NCT04223193, NCT04542499), the label titration to a 5–15 mg maintenance dose, key safety warnings (low blood pressure, impulse-control urges, hallucinations, dyskinesia), and how to talk with a movement-disorder clinician when US supply starts — without treating a US bottle as another country’s carton or assuming every plan pays. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/juvmo-tavapadon-parkinsons